About eltrombopag
Thrombopoietin receptor agonist
Used for
- Raises platelet counts in chronic immune thrombocytopenia (ITP)
- Treats low platelets in chronic hepatitis C
- Treats severe aplastic anaemia
Usual adult dose
ITP: usually 50 mg once daily; hepatitis C: usually 25 mg once daily; aplastic anaemia dosing varies by regimen.
Usual dose in children
ITP, ages 1–17: usually 25 or 50 mg once daily, based on age and ancestry.
Common side effects
- Nausea or diarrhoea
- Headache
- Raised liver enzymes
- Blood clots
Important warnings
- May cause serious liver injury; liver tests are needed.
- Platelet counts may rise excessively, increasing blood-clot risk.
- Take apart from calcium-rich foods, dairy, and mineral supplements.
- Not a cure for ITP; platelet counts can fall after stopping.
Pregnancy
Human pregnancy information is limited; use only when expected benefit outweighs potential risk.
Breastfeeding
It is unknown whether eltrombopag passes into human milk; breastfeeding is generally not recommended during treatment.
Interactions
- Calcium, iron, magnesium, aluminium, zinc, and dairy reduce absorption.
- May increase exposure to rosuvastatin and other OATP1B1/BCRP substrates.
- Antacids and mineral supplements should be separated from the dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.